Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen
< Previous
1
2
Next >
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 13, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
August 06, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 09, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
June 27, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
June 11, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
June 07, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 25, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 12, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
September 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 22, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
August 10, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 17, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
July 13, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.